Ignite Creation Date:
2024-05-06 @ 8:23 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06363734
Status:
RECRUITING
Last Update Posted:
2024-04-16
First Post:
2024-04-09
Brief Title:
Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant CDK46 Pathway Aberrant Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI a Phase II Trial
Sponsor:
Organization:
Tianjin Medical University Cancer Institute and Hospital